AR054846A1 - Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4- piridin-3-il-pirimidin-2- ilamino)-benzamida - Google Patents

Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4- piridin-3-il-pirimidin-2- ilamino)-benzamida

Info

Publication number
AR054846A1
AR054846A1 ARP060103070A ARP060103070A AR054846A1 AR 054846 A1 AR054846 A1 AR 054846A1 AR P060103070 A ARP060103070 A AR P060103070A AR P060103070 A ARP060103070 A AR P060103070A AR 054846 A1 AR054846 A1 AR 054846A1
Authority
AR
Argentina
Prior art keywords
methyl
imidazol
phenyl
benzamida
trifluorometil
Prior art date
Application number
ARP060103070A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37451227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054846(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR054846A1 publication Critical patent/AR054846A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Sales de las mismas y composiciones farmacéuticas que las contienen. Reivindicacion 1: Una forma cristalina sustancialmente pura A de 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida como base libre. Reivindicacion 4: Una forma cristalina sustancialmente pura B de 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida como base libre.
ARP060103070A 2005-07-20 2006-07-18 Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4- piridin-3-il-pirimidin-2- ilamino)-benzamida AR054846A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70140505P 2005-07-20 2005-07-20
US71621405P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
AR054846A1 true AR054846A1 (es) 2007-07-18

Family

ID=37451227

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103070A AR054846A1 (es) 2005-07-20 2006-07-18 Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4- piridin-3-il-pirimidin-2- ilamino)-benzamida

Country Status (43)

Country Link
US (4) US8343984B2 (es)
EP (5) EP2535337B1 (es)
JP (3) JP5289948B2 (es)
KR (3) KR101651288B1 (es)
CN (2) CN102358736A (es)
AR (1) AR054846A1 (es)
AU (3) AU2006276204A1 (es)
BR (1) BRPI0613615B1 (es)
CA (1) CA2614334C (es)
CR (1) CR9657A (es)
CU (1) CU23916B1 (es)
CY (2) CY1113076T1 (es)
DK (2) DK2284167T4 (es)
EA (2) EA016856B1 (es)
EC (1) ECSP088119A (es)
ES (3) ES2623608T5 (es)
GE (1) GEP20115302B (es)
GT (1) GT200600315A (es)
HK (1) HK1116783A1 (es)
HN (1) HN2008000311A (es)
HR (2) HRP20120573T1 (es)
HU (1) HUE031791T2 (es)
IL (2) IL188189A0 (es)
JO (1) JO3308B1 (es)
LT (1) LT2284167T (es)
MA (1) MA29626B1 (es)
MX (1) MX2008000899A (es)
MY (1) MY148554A (es)
NI (1) NI200800017A (es)
NO (1) NO341930B1 (es)
NZ (1) NZ564409A (es)
PE (1) PE20070214A1 (es)
PH (1) PH12013501590A1 (es)
PL (2) PL1912973T3 (es)
PT (2) PT1912973E (es)
RS (1) RS55929B2 (es)
SG (1) SG163620A1 (es)
SI (2) SI1912973T1 (es)
SM (1) SMP200800011B (es)
TN (1) TNSN08029A1 (es)
TW (1) TWI406661B (es)
UA (1) UA94234C2 (es)
WO (1) WO2007015870A2 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
KR20090031855A (ko) * 2006-04-07 2009-03-30 노파르티스 아게 백혈병의 치료를 위한, 피리미딜아미노벤즈아미드 화합물과조합된 c-src 억제제의 용도
EP1923053A1 (en) 2006-09-27 2008-05-21 Novartis AG Pharmaceutical compositions comprising nilotinib or its salt
JP2011507880A (ja) 2007-12-21 2011-03-10 ノバルティス アーゲー 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
KR101251726B1 (ko) 2008-11-05 2013-04-05 테바 파마슈티컬 인더스트리즈 리미티드 닐로티닙 HCl 결정형
EP2186514B1 (en) 2008-11-14 2016-06-29 Kinki University Treatment of Malignant Peripheral Nerve Sheath Tumors
BRPI1013366A2 (pt) 2009-03-06 2016-03-29 Novartis Ag uso de derivados de pirimidilaminobenzamida para o tratamento de distúrbios mediados pela quinase contendo zíper de leucina e quinase contendo motivo alfa estéril (zak).
TW201102068A (en) 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
MX2012004709A (es) 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
JO3634B1 (ar) 2009-11-17 2020-08-27 Novartis Ag طريقة لعلاج اضطرابات تكاثرية وحالات مرضية أخرى متوسطة بنشاط كيناز bcr-abl، c-kit، ddr1، ddr2، أو pdgf-r
IN2010KO00035A (es) * 2010-01-15 2016-09-02
JP2013525296A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー 内分泌療法抵抗性乳癌の処置
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
US8937082B2 (en) 2010-06-21 2015-01-20 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
CN102453024B (zh) * 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) * 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
AR086913A1 (es) 2011-06-14 2014-01-29 Novartis Ag 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
CA2853095A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013074432A1 (en) 2011-11-14 2013-05-23 Novartis Ag Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
EP2626355B1 (en) * 2012-02-09 2016-02-03 Natco Pharma Limited Process for the preparation of nilotinib hydrochloride
WO2013120852A1 (en) 2012-02-13 2013-08-22 Grindeks, A Joint Stock Company Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
IN2014DN10801A (es) 2012-07-11 2015-09-04 Novartis Ag
CA2888002A1 (en) 2012-10-15 2014-04-24 Apotex Inc. Solid forms of nilotinib hydrochloride
CA2887540A1 (en) * 2012-10-19 2014-04-24 Basf Se Multicomponent crystalline system comprising nilotinib and selected co-crystal formers
SG11201505680RA (en) * 2013-02-21 2015-09-29 Pfizer Solid forms of a selective cdk4/6 inhibitor
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
EP2989090A4 (en) * 2013-04-24 2017-01-18 Dr. Reddy's Laboratories Ltd. Polymorphic forms of nilotinib hydrochloride
RU2551359C9 (ru) * 2013-11-28 2021-08-20 Общество с ограниченной ответственностью "Мамонт Фарм" Наноразмерная слабо закристаллизованная модификация 4-метил-N-[3-(4-метилимидазол-1-ил)-5-(трифторметил)фенил]-3-[(4-пиридин-3-илпиримидин-2-ил)амино]бензамида гидрохлорида моногидрата, способ ее получения и фармацевтическая композиция на ее основе
WO2015092624A1 (en) 2013-12-16 2015-06-25 Ranbaxy Laboratories Limited Nilotinib mono-oxalate and its crystalline form
US9926296B2 (en) 2014-08-08 2018-03-27 Dr. Reddy's Laboratories Limited Process for the preparation of polymorphic forms of nilotinib hydrochloride
MX2017004770A (es) * 2014-10-16 2017-07-26 Apotex Inc Formas solidas del clorhidrato de nilotinib.
EP3408264B1 (en) 2016-01-26 2020-03-11 Farma GRS, d.o.o. Nilotinib dinitrate (v) and crystalline forms thereof
WO2017149550A1 (en) * 2016-03-02 2017-09-08 Msn Laboratories Private Limited Amorphous form of 4-methyl-n-[3-(4-methyl-1h-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
EP3430004B1 (en) 2016-03-14 2020-07-15 Pliva Hrvatska D.O.O. Solid state forms of nilotinib salts
CN106496193A (zh) * 2016-09-13 2017-03-15 福格森(武汉)生物科技股份有限公司 一种高纯度尼罗替尼的制备方法
EP3404025B1 (en) 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
CN116808044A (zh) 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
JP2020007240A (ja) * 2018-07-04 2020-01-16 住友化学株式会社 ベンズアミド化合物の製造方法
WO2020095187A1 (en) * 2018-11-05 2020-05-14 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same
IL295007A (en) 2020-01-31 2022-09-01 Nanocopoeia Llc Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN114133378B (zh) * 2020-09-04 2023-08-15 成都苑东生物制药股份有限公司 一种盐酸尼洛替尼共晶及其制备方法
EP4355306A1 (en) 2021-06-19 2024-04-24 Helm AG Granulate composition comprising nilotinib
EP4122452A1 (en) 2021-07-23 2023-01-25 KRKA, d.d., Novo mesto Pharmaceutical composition comprising nilotinib and method of manufacturing the same
EP4260848A1 (en) 2022-04-11 2023-10-18 Lotus Pharmaceutical Co., Ltd. Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation
CN116102540A (zh) * 2023-01-05 2023-05-12 浙江工业大学 两种尼洛替尼游离碱新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701406A (en) 1901-07-16 1902-06-03 Thomas K Jones Cut-off-valve mechanism.
US701405A (en) 1902-02-17 1902-06-03 Archibald White Maconochie Ejecting device for stamping-machines.
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds
NZ547195A (en) * 2003-11-18 2010-06-25 Novartis Ag Inhibitors of the mutant form of kit
GT200600315A (es) 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
GT200600316A (es) 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.

Also Published As

Publication number Publication date
TNSN08029A1 (en) 2009-07-14
MY148554A (en) 2013-04-30
DK1912973T3 (da) 2012-07-23
US8829015B2 (en) 2014-09-09
GT200600315A (es) 2007-03-19
SI1912973T1 (sl) 2012-08-31
EP2535337B1 (en) 2017-08-23
EP2284167B2 (en) 2019-11-27
EP2284167A2 (en) 2011-02-16
BRPI0613615B1 (pt) 2022-02-08
US20080269269A1 (en) 2008-10-30
EP2543665A3 (en) 2013-05-29
PT2284167T (pt) 2017-05-15
JP2014221831A (ja) 2014-11-27
NO20080820L (no) 2008-04-15
HRP20170634T4 (hr) 2020-02-07
ES2623608T3 (es) 2017-07-11
AU2012201453C1 (en) 2024-05-23
CN103804356A (zh) 2014-05-21
CR9657A (es) 2008-04-16
DK2284167T4 (da) 2020-03-02
EP2284168A2 (en) 2011-02-16
PT1912973E (pt) 2012-09-03
JO3308B1 (ar) 2018-09-16
HRP20170634T1 (hr) 2017-06-30
CU20080006A7 (es) 2011-02-24
TW200740793A (en) 2007-11-01
NO341930B1 (no) 2018-02-19
HRP20120573T1 (hr) 2012-08-31
PE20070214A1 (es) 2007-04-02
EP2284167A3 (en) 2011-03-02
ECSP088119A (es) 2008-02-20
AU2012201453B2 (en) 2013-09-05
AU2011202047A1 (en) 2011-05-26
RS55929B2 (sr) 2020-12-31
IL214659A0 (en) 2011-09-27
MX2008000899A (es) 2008-03-18
US20130023548A1 (en) 2013-01-24
HN2008000311A (es) 2011-01-24
UA94234C2 (uk) 2011-04-26
HUE031791T2 (en) 2017-08-28
SMAP200800011A (it) 2008-02-27
PL2284167T5 (pl) 2020-07-27
SG163620A1 (en) 2010-08-30
GEP20115302B (en) 2011-10-10
EA201000145A1 (ru) 2010-06-30
ES2623608T5 (es) 2020-06-18
EP2284167B1 (en) 2017-02-01
PL2284167T3 (pl) 2017-07-31
AU2006276204A1 (en) 2007-02-08
EA200800201A1 (ru) 2008-06-30
RS55929B1 (sr) 2017-09-29
CA2614334A1 (en) 2007-02-08
ES2648288T3 (es) 2017-12-29
PH12013501590A1 (en) 2015-09-21
NZ564409A (en) 2011-07-29
CY1119624T1 (el) 2018-04-04
EA016856B1 (ru) 2012-08-30
JP5798101B2 (ja) 2015-10-21
WO2007015870A3 (en) 2007-06-07
JP2013018789A (ja) 2013-01-31
CY1113076T1 (el) 2016-04-13
US8343984B2 (en) 2013-01-01
EA013464B1 (ru) 2010-04-30
KR20080027853A (ko) 2008-03-28
HK1116783A1 (es) 2009-01-02
KR20130085444A (ko) 2013-07-29
WO2007015870A2 (en) 2007-02-08
EP2535337A1 (en) 2012-12-19
PL1912973T3 (pl) 2012-09-28
SMP200800011B (it) 2008-02-27
KR20130077915A (ko) 2013-07-09
JP2009502795A (ja) 2009-01-29
KR101651288B1 (ko) 2016-08-25
SI2284167T2 (sl) 2020-03-31
AU2012201453A1 (en) 2012-04-05
MA29626B1 (fr) 2008-07-01
US20130165465A1 (en) 2013-06-27
SI2284167T1 (sl) 2017-05-31
JP5289948B2 (ja) 2013-09-11
US20140343087A1 (en) 2014-11-20
US8415363B2 (en) 2013-04-09
CU23916B1 (es) 2013-07-31
EP2543665A2 (en) 2013-01-09
LT2284167T (lt) 2017-04-25
EP1912973A2 (en) 2008-04-23
NI200800017A (es) 2009-03-03
EP2284168A3 (en) 2011-04-13
IL188189A0 (en) 2008-03-20
ES2386974T3 (es) 2012-09-10
CN102358736A (zh) 2012-02-22
DK2284167T3 (en) 2017-05-01
TWI406661B (zh) 2013-09-01
CA2614334C (en) 2015-04-21
BRPI0613615A2 (pt) 2011-01-18
EP1912973B1 (en) 2012-06-13

Similar Documents

Publication Publication Date Title
AR054846A1 (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4- piridin-3-il-pirimidin-2- ilamino)-benzamida
ECSP088118A (es) Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
CY1114793T1 (el) Παραγωγα αμινοπυραζολιου
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
UY29369A1 (es) Nueva sal de 1-(-3-(3-(4-clorofenil) propoxi(propil) -piperidina
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
ECSP088221A (es) Agonistas adrenoreceptores alfa2c
ECSP088549A (es) Nuevos derivados de pirrol fusionado
CR8545A (es) Piperidinilcarbonil-pirrolidinas y su empleo comoagonistas de melanocortina
CL2009000256A1 (es) Imidazolinas fenil sustituidas, composicion farmaceutica que contenga estos compuestos y su uso en el sindrome metabolico, obesidad, diabetes, sindrome de stein-leventhal, transtornos del snc, esquizofrenia, alzheimer, dependencia al alcohol y dependencia a la nicotina.
NO20080265L (no) 2-(1H-indolylsulfanyl)-arylaminderivater
GT200600173A (es) Forma purificada de tranaproget
UY30552A1 (es) Combinaciones farmacologiicas en base a derivados sustituidos de la n-(5-{2-[1,1-dimetil-propilamino]-1-hidroxi-metil}-2-hidroxi-fenil)-metansulfonamida y aplicaciones
CU20120087A7 (es) Procedimiento de síntesis y forma cristalina del hidrocloruro de 4-(3-(cis-hexahidrociclopenta(c)pirrol-2(1h)-il)propoxi)benzamida así como las composiciones farmacéuticas que la contienen
ECSP109874A (es) Nuevos compuestos 892
CU20120123A7 (es) Formas cristalinas de la 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-il-pirimidin-2-il-amino)-benzamida
EA201170007A1 (ru) Новая кристаллическая форма 2-[4-(4-фторбензил)пиперидин-1-ил]-2-оксо-n-(2-оксо-2,3-дигидробензоксазол-6-ил)ацетамида
CL2010000211A1 (es) Formas cristalinas de sal clorhidrato 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil fenil]-3-4-piridin-3-il-pirimidin-2-ilamino)-benzamida; composicion farmaceutica que las comprende; utiles para tratar enfermedades que responden a la inhibicion de proteina quinasa.
UY29682A1 (es) Formas cristalinas de 4-metil-n-(3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil)-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
CR10431A (es) Sales y modificaciones del cristal de las mismas
TR200604414A1 (tr) Misvaklı diş fırçası.
UY29129A1 (es) Sulfonamidas, carboxamidas y acetamidas 1-(tetrahidro-2h-piran4-il-metil-2-ter-butil-1h-bencimidazol-5-il-sustituidas, procedimiento de preparacion, composiciones que los contienen y aplicaciones
TH74246EX (th) กล่องใส่หนังสือ
RU2008127281A (ru) Производные нетропсина, обладающие антивирусной активностью

Legal Events

Date Code Title Description
FB Suspension of granting procedure